Other evidence provided by Seko and colleagues also showed that SGLT2i therapy with canagliflozin (100 mg/day) significantly decreased and normalized the ALT, AST, and GGT levels in serum samples of T2DM patients with NASH (Seko et al., 2018[78]). This evidence concerns the gene GPT and type 2 diabetes mellitus.